BRCA1 and neoplasm: We have identified specific signatures for ESR1-positive and ESR1-negative BRCA1 tumours, the latter characterised by the enrichment of immune response and cell-cycle genes, and have found that slight differences in the level of expression of the immune response stratify the ER-negative BRCA1 tumours into two additional subgroups (A and B).